People · Operator
Named in public records as an officer, director or promoter · active 2013–2016 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Spectrum Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $30.5M | $102.0M | 2013 |
Anthony E. Maida at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anthony E. Maida on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Raymond W. Cohen | 1 | 5 |
| Gilles R. Gagnon | 1 | 1 |
| Stuart M. Krasner | 1 | 1 |
| Luigi M. Lenaz | 1 | 1 |
| Rajesh C. Shrotriya | 1 | 1 |
| Kurt A. Gustafson | 1 | 1 |
| Joseph W. Turgeon | 1 | 1 |
| Dolatrai R. Vyas | 1 | 1 |
| Joseph K. Keller | 1 | 1 |
| Stuart M. Krassner | 1 | 1 |
| Lee F. Allen | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.